OverviewSuggest Edit

Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers. Its lead program, OP-1250, a potential complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.

TypePublic
Founded2007
HQSan Francisco, CA, US
Websiteolema.com

Latest Updates

Employees (est.) (Nov 2020)21
Share Price (Oct 2021)$26.8(-5%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Olema Oncology

Sean P. Bohen

Sean P. Bohen

President and CEO
Cyrus Harmon

Cyrus Harmon

Chief Technology Officer
Pamela M. Klein

Pamela M. Klein

Chief Medical Officer
Peter Kushner

Peter Kushner

Chief Scientific Officer
Shane Kovacs

Shane Kovacs

Chief Operating and Financial Officer
David C. Myles

David C. Myles

Chief Development Officer
Show more

Olema Oncology Office Locations

Olema Oncology has an office in San Francisco
San Francisco, CA, US (HQ)
665 3rd St #250, San Francisco
San Francisco, CA, US
303 2nd St, San Francisco
Show all (2)

Olema Oncology Financials and Metrics

Olema Oncology Revenue

USD

Net income (FY, 2019)

(4.3m)

EBIT (FY, 2019)

(4.3m)

Market capitalization (19-Oct-2021)

1.1b

Closing stock price (19-Oct-2021)

26.8

Cash (30-Sept-2020)

127.8m
Olema Oncology's current market capitalization is $1.1 b.
USDFY, 2018FY, 2019

General and administrative expense

386.0k403.0k

R&D expense

1.7m3.9m

Operating expense total

2.1m4.3m

EBIT

(2.1m)(4.3m)
Annual
USDFY, 2018FY, 2019

Cash

3.1m68.0k

Current Assets

3.2m103.0k

PP&E

26.0k26.0k

Total Assets

3.3m132.0k
Quarterly
USDQ3, 2020

Cash

127.8m

Current Assets

129.1m

PP&E

24.0k

Total Assets

130.7m
Annual
USDFY, 2018FY, 2019

Net Income

(2.2m)(4.3m)

Depreciation and Amortization

8.0k9.0k

Accounts Payable

(32.0k)1.2m

Cash From Operating Activities

(2.2m)(3.1m)
Quarterly
USDQ3, 2019Q3, 2020

Net Income

(3.3m)(12.0m)

Depreciation and Amortization

6.0k7.0k

Accounts Payable

1.0m1.1m

Cash From Operating Activities

(2.2m)(10.9m)
USDFY, 2018

Financial Leverage

-0.5 x
Show all financial metrics

Olema Oncology Operating Metrics

Q3, 2020

Discovery Stage Products

1

Pre-Clinical Phase Products

6

Phase I Trials Products

1
Show all operating metrics

Olema Oncology Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Olema Oncology Online and Social Media Presence

Embed Graph

Olema Oncology News and Updates

Olema Oncology to Present Data on OP-1250 at the 2021 JCA-AACR Precision Cancer Medicine International Conference

SAN FRANCISCO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster pres…

Olema Oncology to Participate at the Jefferies 2021 Virtual Healthcare Conference

SAN FRANCISCO, May 18, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced that Sean P. Bo…

Olema Oncology to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference

SAN FRANCISCO, April 07, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced Sean P. Bohen…

Olema Oncology Appoints Oncology Biotech Executive Yi Larson, MBA, to Board of Directors

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced the appointme…

Olema Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates

SAN FRANCISCO, March 17, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology,” NASDAQ: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today reported financial resu…

Olema Oncology Announces Late-Breaking Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2021

SAN FRANCISCO, March 10, 2021 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on OP…
Show more

Olema Oncology Frequently Asked Questions

  • When was Olema Oncology founded?

    Olema Oncology was founded in 2007.

  • Who are Olema Oncology key executives?

    Olema Oncology's key executives are Sean P. Bohen, Cyrus Harmon and Pamela M. Klein.

  • How many employees does Olema Oncology have?

    Olema Oncology has 21 employees.

  • Who are Olema Oncology competitors?

    Competitors of Olema Oncology include PharmaCyte Biotech, OncBioMune Pharmaceuticals and Briacell.

  • Where is Olema Oncology headquarters?

    Olema Oncology headquarters is located at 665 3rd St #250, San Francisco, San Francisco.

  • Where are Olema Oncology offices?

    Olema Oncology has an office in San Francisco.

  • How many offices does Olema Oncology have?

    Olema Oncology has 2 offices.